Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
Nurix Therapeutics Inc. (NRIX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 7,732,808 | $119,858,524 | -5% | 7.94% |
| 2. | Vestal Point Capital Ryan Wilder | 6,500,000 | $100,750,000 | +39% | 2.82% |
| 3. | Deep Track Capital David Kroin | 6,345,244 | $98,351,282 | -10% | 1.61% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,658,556 | $72,207,618 | 0.41% | |
| 5. | Perceptive Advisors Joseph Edelman | 3,710,877 | $57,518,594 | +5% | 1.12% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.18 | 582 | $9,995.91 | 37,592 | 2026-05-05 | Filing | |
| $16.58 | 13,473 | $223,323.06 | 38,174 | 2026-05-05 | Filing | |
| $16.96 | 8,148 | $138,209.64 | 18,305 | 2026-05-04 | Filing | |
| $16.76 | 5,394 | $90,406.68 | 26,453 | 2026-05-01 | Filing | |
| $16.65 | 2,388 | $39,748.98 | 51,647 | 2026-04-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,925,642 | $138,347,454 | 0% | |
| 2. | 5,541,271 | $85,889,703 | 0% | |
| 3. | 5,141,195 | $79,688,523 | 0% | |
| 4. | 4,931,999 | $76,446,010 | 0% | |
| 5. | 4,427,112 | $68,620,236 | 0% |
News See All
Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best low priced biotech stocks to invest in. Wells Fargo cut the price target on Nurix Therapeutics, Inc.
8 Best Low Priced Biotech Stocks to Invest In
On April 16, Fundstrat’s Tom Lee appeared on CNBC's 'Closing Bell' to talk about what to expect from equity markets going forward.
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory
We came across a bullish thesis on Nurix Therapeutics, Inc. on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NRIX.
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts
TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintained a Buy rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
10 Best Small-Cap Stocks Ready to Explode in 2026
On January 27, Matt Stucky from Northwestern Mutual appeared on a CNBC Television interview to discuss the performance of small-cap stocks.
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best small cap stocks to buy with huge upside potential.
12 Small Cap Stocks to Buy with Huge Upside Potential
Talking about rotation in the market, she expects the trend to continue for a while, with the capital basically moving from the high multiple mega cap winners towards small caps, cyclicals, and the international...
Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial
Nurix Therapeutics extended its winning streak to a fourth straight day on Monday, jumping 18.68 percent to finish at $21.47 apiece as investors took heart from the promising results of its clinical trial...
Hedge Fund Resource Center